Aigen Investment Management LP Makes New Investment in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Key Points

• Aigen Investment Management LP has acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) worth approximately $553,000, purchasing 6,435 shares during the first quarter.
• The stock's consensus rating is "Hold" with an average target price of $93.33, as several analysts have modified their ratings recently.
• Prestige Consumer Healthcare reported a net margin of 19.02% for the last quarter, but its revenue fell by 6.6% year-over-year, missing analysts' expectations.

Aigen Investment Management LP purchased a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,435 shares of the company's stock, valued at approximately $553,000.

Other hedge funds have also bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth about $84,932,000. Raymond James Financial Inc. bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth about $42,593,000. Invesco Ltd. grew its holdings in shares of Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after purchasing an additional 261,537 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Prestige Consumer Healthcare by 1,073.3% in the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock worth $15,923,000 after purchasing an additional 186,524 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Prestige Consumer Healthcare by 11,580.3% in the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock worth $13,887,000 after purchasing an additional 160,155 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

PBH traded up $0.46 during trading on Friday, reaching $65.06. 698,764 shares of the company's stock were exchanged, compared to its average volume of 387,118. Prestige Consumer Healthcare Inc. has a 1 year low of $62.95 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The stock has a market capitalization of $3.20 billion, a P/E ratio of 15.27, a price-to-earnings-growth ratio of 2.10 and a beta of 0.43. The company's fifty day simple moving average is $77.27 and its 200-day simple moving average is $81.58.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. During the same period last year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare's revenue for the quarter was down 6.6% compared to the same quarter last year. As a group, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on PBH. Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Finally, Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.